

DNA topoisomerase I inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/DA978BBC939CEN.html>

Date: January 2022

Pages: 80

Price: US\$ 2,000.00 (Single User License)

ID: DA978BBC939CEN

Abstracts

This report can be delivered to the clients within 3-4 Business Days

DelveInsight's, "DNA topoisomerase I inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in DNA topoisomerase I inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

DNA topoisomerase I inhibitors Understanding

DNA topoisomerase I inhibitors: Overview

DNA topoisomerases regulate the number of topological links between two DNA strands (i.e. change the number of superhelical turns) by catalysing transient single- or double-strand breaks, crossing the strands through one another, then resealing the breaks. Type I topoisomerases are ATP-independent enzymes (except for reverse gyrase), and can be subdivided according to their structure and reaction mechanisms: type IA (Topo IA; bacterial and archaeal topoisomerase I, topoisomerase III and reverse gyrase) and type IB (Topo IB; eukaryotic topoisomerase I and topoisomerase V). These enzymes are primarily responsible for relaxing positively and/or negatively supercoiled DNA,

except for reverse gyrase, which can introduce positive supercoils into DNA. This function is vital for the processes of replication, transcription, and recombination.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence DNA topoisomerase I inhibitors R&D. The therapies under development are focused on novel approaches for DNA topoisomerase I inhibitors.

DNA topoisomerase I inhibitors Emerging Drugs Chapters

This segment of the DNA topoisomerase I inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

DNA topoisomerase I inhibitors Emerging Drugs

Sacituzumab govitecan: Immunomedics

Sacituzumab govitecan is an antibody–drug conjugate composed of an antitrophoblast cell-surface antigen 2 (Trop-2) IgG1 kappa antibody coupled to SN-38, the active metabolite of irinotecan and a topoisomerase I inhibitor through a proprietary hydrolyzable linker. Currently, it is in Phase III stage of development to treat Solid tumours.

Trastuzumab Deruxtecan: Daiichi Sankyo

Trastuzumab deruxtecan is a HER2 directed antibody drug conjugate (ADC). Designed using Daiichi Sankyo's proprietary DXd ADC technology, trastuzumab deruxtecan is the lead ADC in the oncology portfolio of Daiichi Sankyo and the most advanced program in AstraZeneca's ADC scientific platform. Trastuzumab deruxtecan (5.4 mg/kg) is approved in the U.S. and Japan for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer. Trastuzumab deruxtecan (6.4

mg/kg) is also approved in Japan for the treatment of patients with HER2 positive unresectable advanced or recurrent gastric cancer.

Further product details are provided in the report.....

DNA topoisomerase I inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different DNA topoisomerase I inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on DNA topoisomerase I inhibitors

There are approx. 20+ key companies which are developing the DNA topoisomerase I inhibitors. The companies which have their DNA topoisomerase I inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Immunomedics.

Phases

DelveInsight's report covers around 20+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

DNA topoisomerase I inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized

under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and

Mono/Combination.

DNA topoisomerase I inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses DNA topoisomerase I inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging DNA topoisomerase I inhibitors drugs.

DNA topoisomerase I inhibitors Report Insights

DNA topoisomerase I inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

DNA topoisomerase I inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing DNA topoisomerase I inhibitors drugs?

How many DNA topoisomerase I inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of DNA topoisomerase I inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the DNA topoisomerase I inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for DNA topoisomerase I inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Immunomedics

Daiichi Sankyo

Ipsen

Luye Pharma Group

Hanmi Pharmaceutical

Biocompatibles International

Valent Technologies

Elucida Oncology

Cybrexa Therapeutics

Linus Oncology

Lee's Pharmaceutical

SN BioScience

Cebiotex

Key Products

Sacituzumab govitecan

Trastuzumab deruxtecan

Irinotecan sucrosfate

DS-1062

LY 01610

Irinotecan/encequidar

CM-BC2

VAL-413

DS 6000

CEB-01

SN 38

ELU 001

Gimatecan

LMP 744

CBX-12

Contents

- Introduction
- Executive Summary
- DNA topoisomerase I inhibitors: Overview
 - Structure
 - Mechanism of Action
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- DNA topoisomerase I inhibitors – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
 - Comparative Analysis
- Sacituzumab govitecan: Immunomedics
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
 - Comparative Analysis
- Irinotecan hydrochloride liposomal: Luye Pharma Group
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I and I/II)
 - Comparative Analysis
- Irinotecan: Valent Technologies
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Pre-clinical and Discovery Stage Products

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

DNA topoisomerase I inhibitors Key Companies

DNA topoisomerase I inhibitors Key Products

DNA topoisomerase I inhibitors- Unmet Needs

DNA topoisomerase I inhibitors- Market Drivers and Barriers

DNA topoisomerase I inhibitors- Future Perspectives and Conclusion

DNA topoisomerase I inhibitors Analyst Views

DNA topoisomerase I inhibitors Key Companies

Appendix

I would like to order

Product name: DNA topoisomerase I inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/DA978BBC939CEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DA978BBC939CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970